JP2023554066A5 - - Google Patents

Info

Publication number
JP2023554066A5
JP2023554066A5 JP2023536584A JP2023536584A JP2023554066A5 JP 2023554066 A5 JP2023554066 A5 JP 2023554066A5 JP 2023536584 A JP2023536584 A JP 2023536584A JP 2023536584 A JP2023536584 A JP 2023536584A JP 2023554066 A5 JP2023554066 A5 JP 2023554066A5
Authority
JP
Japan
Application number
JP2023536584A
Other languages
Japanese (ja)
Other versions
JP2023554066A (ja
JPWO2022130014A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000874 external-priority patent/WO2022130014A1/en
Publication of JP2023554066A publication Critical patent/JP2023554066A/ja
Publication of JPWO2022130014A5 publication Critical patent/JPWO2022130014A5/ja
Publication of JP2023554066A5 publication Critical patent/JP2023554066A5/ja
Pending legal-status Critical Current

Links

JP2023536584A 2020-12-16 2021-12-15 血漿カリクレインの制御不全によって媒介される疾患の処置のための抗体のアデノ随伴ウイルスベクター送達 Pending JP2023554066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126300P 2020-12-16 2020-12-16
US63/126,300 2020-12-16
PCT/IB2021/000874 WO2022130014A1 (en) 2020-12-16 2021-12-15 Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein

Publications (3)

Publication Number Publication Date
JP2023554066A JP2023554066A (ja) 2023-12-26
JPWO2022130014A5 JPWO2022130014A5 (https=) 2024-12-23
JP2023554066A5 true JP2023554066A5 (https=) 2024-12-23

Family

ID=80461568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536584A Pending JP2023554066A (ja) 2020-12-16 2021-12-15 血漿カリクレインの制御不全によって媒介される疾患の処置のための抗体のアデノ随伴ウイルスベクター送達

Country Status (5)

Country Link
US (1) US20220186252A1 (https=)
EP (1) EP4263614A1 (https=)
JP (1) JP2023554066A (https=)
CN (1) CN116829595A (https=)
WO (1) WO2022130014A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116790615B (zh) * 2023-07-11 2024-11-22 康霖生物科技(杭州)有限公司 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法
GB202402816D0 (en) * 2024-02-28 2024-04-10 Imperial College Innovations Ltd Self-amplifying RNA molecule

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1438075A4 (en) 2001-10-02 2006-04-19 Inst Clayton De La Rech METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS
US7816131B2 (en) 2004-04-02 2010-10-19 Board Of Regents, The University Of Texas System Cancer specific promoters
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
GB201206455D0 (en) 2012-04-12 2012-05-30 Royal Holloway & Bedford New College Gene expression
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
JP2016517440A (ja) 2013-03-15 2016-06-16 ブイエルピー バイオテック,インコーポレイテッド パリビズマブエピトープベースのウイルス様粒子
CN107249646B (zh) 2014-12-16 2021-06-29 内布拉斯加大学董事会 用于青少年巴滕病的基因疗法
CL2014003590A1 (es) 2014-12-30 2015-07-10 Univ Chile Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
CN108291238A (zh) 2015-10-27 2018-07-17 赛尔希恩公司 嵌合转录后调控元件
CN109415687A (zh) 2016-04-07 2019-03-01 蓝鸟生物公司 嵌合抗原受体t细胞组合物
JP7632835B2 (ja) 2016-05-20 2025-02-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
CN110662839A (zh) 2017-02-17 2020-01-07 珀杜研究基金会 用于细胞疗法的基于靶向性配体-有效负载的药物递送
KR20220012231A (ko) * 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
EP4048800A1 (en) * 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof

Similar Documents

Publication Publication Date Title
JP2022530006A5 (https=)
JP2023554066A5 (https=)
JP1684883S (https=)
CN305527280S (https=)
CN305527951S (https=)
CN305537279S (https=)
CN305536191S (https=)
CN305534854S (https=)
CN305533948S (https=)
CN305533528S (https=)
CN305532224S (https=)
CN305532058S (https=)
CN305531711S (https=)
CN305530253S (https=)
CN305529990S (https=)
CN305528493S (https=)
CN305527895S (https=)
CN305526843S (https=)
CN306451768S (https=)
CN306446550S (https=)
CN306409475S (https=)
CN306408163S (https=)
CN306115244S (https=)
CN306405439S (https=)
CN306387237S (https=)